胚系遗传变异不能预测PCPT和SELECT化学预防试验的结局
本研究对PCPT试验(n=2434)和SELECT试验(n=4885)中的欧洲男性进行基因分型,评估胚系风险SNP能否预测化学预防试验结局。结果显示,多基因风险评分较高的男性更易发生前列腺癌,但该评分不能预测其他结局,且风险SNP与化学预防药物之间无交互作用。
要点
- 多基因风险评分高者前列腺癌发生风险更高,但不能预测其他试验结局。
- 胚系风险SNP与SELECT和PCPT中的化学预防药物无交互作用。
- 部分SNP在两个试验中可预测侵袭性疾病。
核心结论
- 多基因风险评分较高的男性更易发生前列腺癌。
- 胚系风险SNP与SELECT和PCPT试验中的化学预防药物无交互作用。
研究设计与样本
- 对PCPT试验(n=2434)和SELECT试验(n=4885)中的欧洲男性进行基因分型。
- 采用Affymetrix® Eureka™ Genotyping方案进行下一代基因分型。
- 使用逻辑回归模型检验风险评分与试验结局的关联。
主要发现
- 100个SNP中98个设计成功,且在其他平台基因分型的样本中得到验证。
- 部分SNP在两个试验中可预测侵袭性疾病。
- 多基因风险评分较高的男性在两个试验中均更易发生前列腺癌,但该评分不能预测其他结局。
临床怎么用
- 胚系风险SNP暂不能用于预测化学预防试验中的其他结局。
- 多基因风险评分可能有助于识别前列腺癌高风险男性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of prostate cancer can be influenced by genetic and environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase prostate cancer susceptibility are unknown. Finasteride is currently not being used routinely as a chemoprevention agent but the long term outcomes of the PCPT trial are awaited. The outcomes of the SELECT trial have not recommended the use of chemoprevention in preventing prostate cancer. This study investigated whether germline risk SNPs could be used to predict outcomes in the PCPT and SELECT trial. METHODS: Genotyping was performed in European men entered into the PCPT trial (n = 2434) and SELECT (n = 4885). Next generation genotyping was performed using Affymetrix® Eureka™ Genotyping protocols. Logistic regression models were used to test the association of risk scores and the outcomes in the PCPT and SELECT trials. RESULTS: Of the 100 SNPs, 98 designed successfully and genotyping was validated for samples genotyped on other platforms. A number of SNPs predicted for aggressive disease in both trials. Men with a higher polygenic score are more likely to develop prostate cancer in both trials, but the score did not predict for other outcomes in the trial. CONCLUSION: Men with a higher polygenic risk score are more likely to develop prostate cancer. There were no interactions of these germline risk SNPs and the chemoprevention agents in the SELECT and PCPT trials.
引用
- Ahmed M, Goh C, Saunders E, et al. Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate Cancer Prostatic Dis. 2019. PMID: 31776447. doi:10.1038/s41391-019-0181-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。